中国医药
中國醫藥
중국의약
China Medicine
2015年
9期
1330-1332
,共3页
郭智%陈惠仁%杨凯%刘晓东%楼金星%何学鹏%张媛%陈鹏%王芳
郭智%陳惠仁%楊凱%劉曉東%樓金星%何學鵬%張媛%陳鵬%王芳
곽지%진혜인%양개%류효동%루금성%하학붕%장원%진붕%왕방
骨原发性淋巴瘤%脂质体阿霉素%序贯治疗%无病生存
骨原髮性淋巴瘤%脂質體阿黴素%序貫治療%無病生存
골원발성림파류%지질체아매소%서관치료%무병생존
Primary lymphoma of bone%Liposome doxorubicin%Sequential therapy%Disease free survival
目的 观察脂质体阿霉素联合COP化疗方案(环磷酰胺±长春地辛±地塞米松)治疗骨原发性淋巴瘤的有效性和安全性.方法 应用脂质体阿霉素联合COP化疗方案(或同时联合利妥昔单抗)治疗2010年6月至2014年6月北京空军总医院收治的10例骨原发性淋巴瘤患者,男6例,女4例,平均年龄(41±l2)岁(27 ～ 61岁),观察临床疗效及脂质体阿霉素不良反应.结果 全组10例患者,经过脂质体阿霉素联合COP方案序贯治疗6～8个周期,随访至2015年1月,获得完全缓解5例,部分缓解3例,复发死亡1例,并发症死亡l例,8例有效,最长l例患者已无病生存超过50个月.结论 脂质体阿霉素联合COP化疗方案治疗骨原发性淋巴瘤具有较高的安全性和有效性.
目的 觀察脂質體阿黴素聯閤COP化療方案(環燐酰胺±長春地辛±地塞米鬆)治療骨原髮性淋巴瘤的有效性和安全性.方法 應用脂質體阿黴素聯閤COP化療方案(或同時聯閤利妥昔單抗)治療2010年6月至2014年6月北京空軍總醫院收治的10例骨原髮性淋巴瘤患者,男6例,女4例,平均年齡(41±l2)歲(27 ～ 61歲),觀察臨床療效及脂質體阿黴素不良反應.結果 全組10例患者,經過脂質體阿黴素聯閤COP方案序貫治療6～8箇週期,隨訪至2015年1月,穫得完全緩解5例,部分緩解3例,複髮死亡1例,併髮癥死亡l例,8例有效,最長l例患者已無病生存超過50箇月.結論 脂質體阿黴素聯閤COP化療方案治療骨原髮性淋巴瘤具有較高的安全性和有效性.
목적 관찰지질체아매소연합COP화료방안(배린선알±장춘지신±지새미송)치료골원발성림파류적유효성화안전성.방법 응용지질체아매소연합COP화료방안(혹동시연합리타석단항)치료2010년6월지2014년6월북경공군총의원수치적10례골원발성림파류환자,남6례,녀4례,평균년령(41±l2)세(27 ～ 61세),관찰림상료효급지질체아매소불량반응.결과 전조10례환자,경과지질체아매소연합COP방안서관치료6～8개주기,수방지2015년1월,획득완전완해5례,부분완해3례,복발사망1례,병발증사망l례,8례유효,최장l례환자이무병생존초과50개월.결론 지질체아매소연합COP화료방안치료골원발성림파류구유교고적안전성화유효성.
Objective To explore the efficacy and safety of liposomal doxorubicin combined with COP chemotherapy regimen in treating primary lymphoma of bones.Methods Ten patients [6 males and 4 females,(41 ± 12) years old (27-61) years old] with primary lymphoma of bone from June 2010 to June 2014 were enrolled and received liposomal doxorubicin combined with COP chemotherapy regimen.The efficacy and safety of liposomal doxorubicin were observed.Results Totally 6 to 8 courses of treatment were given and patients were followed up till January 2015.There were 5 of complete remission and 3 of partial remission; 1 case died of recurrence; 1 case died of complications.Totally 8 cases were effective.The longest disease free survival time was more than 50 months.Conclusion Liposomal doxorubicin combined with COP chemotherapy regimen is safe and effective for treating primary lymphoma of bone.
